RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth ...

Q1 2026 earnings call recap: revenue, EPS beat, updated guidance, Polymem divestiture and margin plans—read key takeaways now.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2026 results topping the market’s revenue ...

First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and ...

What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.3% in the morning ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results this Tuesday before ...

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the ...

NEW YORK (Reuters) -Repligen, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of about $2.5 billion, ...

Good day, ladies and gentlemen, and welcome to Repligen Corporation's First Quarter 2026 Earnings Conference Call. My name is Samantha, and I will be your coordinator. [Operator Instructions] I will ...

Avitide, a company that spun out of an Ivy League lab with a way to quickly and efficiently purify biologic drugs, is being acquired for $150 million by global bioprocessing vendor Repligen, which ...

First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26 ...